This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Burden of Disease
Burden of Disease
Risk Factors
Secondary Infections
Mechanism of Action
Prevention of Pneumococcal Disease
Need for Pneumococcal Vaccination
Cost-effectiveness of PCV13
Legacy of Prevenar
Safety
Conclusion
Dosing
Prevenar 13® Clinical Experience
Efficacy of Prevenar 13®
Effectiveness of Prevenar 13®
Indian Clinical Trials
Recommendations for Use
PCV13 in Pulmonology
PCV13 in Nephrology
PCV13 in Oncology
PCV13 in Rheumatology
PCV13 in Diabetes
PCV13 in HIV Infection
PCV13 in Cardiology
Resources
Infectious Complications in Patients With Diabetes
Host defence of each diabetic, however, is compromised, and thus, diabetics are prone to all microbial colonisation, infection and invasion. With the dual jeopardy of a large diabetes pool especially in the elderly, the role of pneumococcal disease becomes relevant in the Indian context. Diabetics have a poor antibody response, with a host of cell-mediated immune abnormalities. They have decreased CD4/CD8 lymphocyte ratios, which lead to changes in natural killer cell function, reduced lymphocyte blastogenesis, defects in interleukin-2 function and reduced phagocytic function of monocytes. Diabetics have classically impaired leukocyte function and thus are predisposed to colonisation and pneumonia. Patients with diabetes have a high risk for microbiological infections (fungal, viral and bacterial), leading to complications with high morbidity and mortality. Clinically, the most important infections are fungal and bacterial infections of the skin, urinary tract and respiratory tract. Other factors associated with diabetes (age, renal disease and cardiovascular disease) have been shown to be significant comorbid factors that can increase the risk of sequel of certain infections.1
People with diabetes are susceptible to pneumococcal infections and are at an increased risk for morbidity and mortality. Additional risk is associated with age ≥65 years and having chronic cardiovascular, pulmonary and renal diseases. Diabetes mellitus has been identified as an independent risk factor for developing respiratory tract infections. There are no data on the burden of lower respiratory infections in India. The WHO data from low- and middle-income countries suggest that lower respiratory tract infections remain the third leading cause of death. S. pneumoniae remains the major cause of pneumonia. Apart from pneumonia and its complications, viz., empyema and lung abscess, the pneumococcus also causes other clinical syndromes such as sinusitis, otitis media, trachea-bronchitis, bacteraemia, meningitis and peritonitis, some of which have high CFRs. Diabetes is a well-known risk factor for pneumococcal infections and predisposes individuals to nasopharyngeal colonisation with the pneumococcus which is associated with invasive infections. Pneumococcal pneumonia is the most common form of acute bacterial CAP. Bacteraemia is seen in nearly 30% (8%-50%) of individuals with pneumococcal infections, and of these, 15% to 20% are fatal despite treatment with antibiotics. Also, there are several studies which show that diabetes is one of the most common comorbidities in patients with pneumococcal infections.1
CAP, community-acquired pneumonia; CD4, cluster of differentiation 4; CD8, cluster of differentiation 8; CFR, case fatality rate; WHO, World Health Organization.
Reference:
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0268 July 2022
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Efficacy proven by the CAPiTA study
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.